The future role of anti-tumour necrosis factor-α products in the treatment of Crohn's disease (vol 56, pg 299, 1998)

被引：0
作者：
van Hogezand, RA
Verspaget, HW
机构：
来源：
DRUGS | 1999年 / 57卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：79 / 79
页数：1
相关论文
共 50 条
  • [41] Pustular lesions in patients with Crohn disease and treatment with tumour necrosis factor-α inhibitors
    Balaguer-Franch, I.
    Hernandez de la Torre-Ruiz, E.
    Lacasta-Plasin, C.
    Garcia-Piqueras, P.
    Menchen-Viso, L.
    Baniandres-Rodriguez, O.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2022, 47 (02) : 453 - 455
  • [42] Anti-tumour necrosis factor- treatment and weight gain in psoriasis: the "pudgy blanching' conundrum
    Puig, L.
    BRITISH JOURNAL OF DERMATOLOGY, 2013, 168 (05) : 923 - 924
  • [43] Antibodies to tumor necrosis factor-α in the treatment of Crohn's disease
    Brown, SJ
    Abreu, MT
    CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT, 2005, 8 (02) : 160 - 168
  • [44] Efficacy and safety of ustekinumab in patients with Crohn's disease refractory to anti-tumour necrosis factor: real clinical practice
    Saiz Chumillas, R. M.
    Alba Hernandez, L.
    Chivato Martin-Falquina, I.
    Badia Aranda, E.
    Arias Garcia, M. L.
    Sicilia Aladren, B.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S400 - S401
  • [45] Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
    Carl Eriksson
    Jonas Söderling
    Sara Karlqvist
    Gabriella Bröms
    Åsa H. Everhov
    Daniel Bergemalm
    Jonas F. Ludvigsson
    Ola Olén
    Jonas Halfvarson
    Digestive Diseases and Sciences, 2023, 68 : 3119 - 3128
  • [46] Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience
    Sprakes, Michael B.
    Hamlin, P. John
    Warren, Lisa
    Greer, Dan
    Ford, Alexander C.
    JOURNAL OF CROHNS & COLITIS, 2011, 5 (04) : 324 - 331
  • [47] Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease
    Eriksson, Carl
    Soderling, Jonas
    Karlqvist, Sara
    Broms, Gabriella
    Everhov, Asa H.
    Bergemalm, Daniel F.
    Ludvigsson, Jonas
    Olen, Ola
    Halfvarson, Jonas
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (07) : 3119 - 3128
  • [48] Treatment of perianal fistula in Crohn's disease: a systematic review and meta-analysis comparing seton drainage and anti-tumour necrosis factor treatment
    de Groof, E. J.
    Sahami, S.
    Lucas, C.
    Ponsioen, C. Y.
    Bemelman, W. A.
    Buskens, C. J.
    COLORECTAL DISEASE, 2016, 18 (07) : 667 - 675
  • [49] Loss-of-response to anti-tumour necrosis factor-α critically depends on treatment duration in patients with Inflammatory Bowel Disease
    Schultheiss, J.
    Mahmoud, R.
    Louwers, J.
    van der Kaaij, M.
    van Hellemondt, B.
    van Boeckel, P.
    Mahmmod, N.
    Jharap, B.
    Fidder, H.
    Oldenburg, B.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S327 - S328
  • [50] Paradoxical onset of Takayasu's arteritis in patients with inflammatory bowel disease treated with anti-tumour necrosis factor-α agents
    Matsune, Y.
    Kouyama, J.
    Tsuru, Y.
    Shimizu, K.
    Asami, S.
    Matsuyama, S.
    Katsuki, S.
    Ishihara, H.
    Onizawa, R.
    Shonai, S.
    Tatsuno, M.
    Nishikawa, Y.
    Takeuchi, K.
    Watanabe, M.
    Nakamori, Y.
    Hirayama, A.
    Toyoda, J.
    Ikeda, A.
    Madarame, A.
    Nishio, M.
    Ogashiwa, T.
    Matsubayashi, M.
    Fujii, A.
    Kimura, H.
    Kunisaki, R.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S422 - S422
12345